CENTRALCHINA MT (09982) releases its mid-year performance for 2024, with a net profit of approximately 48.3 million Hong Kong dollars, representing a year-on-year decrease of around 74.7%.
Zhongyuan Jianye (09982) released its performance for the six months ending on June 30, 2024, with the group's revenue totaling 1....
CENTRALCHINA MT (09982) released its performance for the six months ending on June 30, 2024. The group's revenue was RMB 146 million, a year-on-year decrease of 61.8%, and the net profit was approximately HKD 48.3 million, a year-on-year decrease of about 74.7%. Earnings per share were 1.2 cents.
Related Articles
Johnson & Johnson (JNJ.US) "Gus-etched Mab" New Domestic Indications Approved
Novartis AG Sponsored ADR pharmaceutical (NVS.US) Class 1 new drug approved for clinical use in rheumatoid arthritis.
China Great Wall: improving the national safety standards for power batteries may help in eliminating low-efficiency production capacity at the tail end.
Johnson & Johnson (JNJ.US) "Gus-etched Mab" New Domestic Indications Approved
Novartis AG Sponsored ADR pharmaceutical (NVS.US) Class 1 new drug approved for clinical use in rheumatoid arthritis.
China Great Wall: improving the national safety standards for power batteries may help in eliminating low-efficiency production capacity at the tail end.
RECOMMEND
General Administration of Customs: China's goods trade imports and exports increased by 2.4% year-on-year in the first 4 months.
09/05/2025
Key details are yet to be finalized. The market's response to the US-UK trade agreement has been lukewarm.
09/05/2025
Risk assets rebounded to boost the market, Bitcoin surged back above $100,000.
09/05/2025
